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Saudi Journal of Ophthalmology (2013) 27, 133–134EditorialRetinoblastoma: A new challenge to the Knudson’s DogmaIn 1971, Alfred Knudson1 was the first to propose the
hypothesis predicting that two mutations (two hits) of key
genes in the control of cell division occurring in a retinal neu-
ro-ectodermal cell were necessary for the development of
retinoblastoma. According to this hypothesis, the first muta-
tion is a germ line mutation present in all the cells of the body
especially in all retinal neuro-ectodermal embryonic cells,
while the second mutation is somatic, acquired during fetal
life or the first months of neonatal life. In 1973, Comings2
reinforced this hypothesis by postulating that the two muta-
tions necessary for the development of retinoblastoma corre-
spond to the inactivation of two alleles of the same gene. In
1984, Murphree and Benedict3 suggested that a single locus
existed for all forms of retinoblastoma located in the 13q14
region after observing retinoblastoma cases presenting with
dysmorphic features and mental retardation. This observa-
tion resulted in genetic studies focusing on this region. In
1986, Friend and associates4 were the first to identify the ret-
inoblastoma gene and called it Rb1. This was the first repre-
sentative of a class of cancer genes that restricts the
uncontrolled growth of embryonic cells rather than produc-
ing cell growth.
The Rb1 gene is composed of 27 exons ranging in size
from 31 to 1889 base pairs, the gene product is a 110-kDa
nuclear phosphoprotein of 928 amino acids that is normally
present in all cells and called RB1. The retinoblastoma gene
product is the retinoblastoma protein pRb, which is part of
the retinoblastoma family of proteins also called pocket pro-
teins that also include proteins p107 and p130.5 These pro-
teins share sequence homology in a bipartite domain
known as a pocket domain, which mediates interaction with
transcription factors from the E2F family during the G1/S
transition of the cell cycle. The pRB binds to E2F factors
and suppresses their activity consequently blocking progres-
sion to the S phase. Inversely, phosphorylation of the pRB re-
leases E2F factors allowing completion of the cell cycle. The
pRb protein is involved in regulation of the cell cycle, control-
ling the termination of cellular differentiation and in exiting of
the cell from the cell cycle during development. It also ap-
pears to interact with more than 100 different proteins. When
pRb is absent cells proliferate uncontrollably, leading to can-
cer. The interaction between pRB and E2f is regulated by
other factors, including cyclin D1, cdk4 and p16. One normal
copy of the gene is adequate to prevent tumor formation.
Malignant transformation of a retinal cell occurs after both
homologous copies of the retinoblastoma gene in that the
cell undergoes loss-of-function mutations, supporting Knud-
son’s ‘‘two-hit’’ hypothesis.Peer review under responsibility
of Saudi Ophthalmological Society,
King Saud UniversityDuring the last two decades, advanced techniques in
molecular biology provided a better understanding of the
oncogenesis and the spectrum of mutations of the RBI gene,
allowing identification of up to 932 (and counting) different
mutations.6 The most frequent mutations are nonsense muta-
tions and also missense, splicing mutations, inframe deletions
and mutations in the regulatory sequence at the promotor.
Hence, investigators can identify relevant phenotype-geno-
type relationships and provide working hypothesis for mech-
anisms linking certain mutations to ethnicity, delayed onset
of the disease and low penetrance with variable expressivity.
Investigations into retinoblastoma oncogenesis have the
common denominator that mutations in two alleles or two
hits to the RB1 gene are required to develop retinoblastoma
based on the Knudson’s hypothesis. Until recently, this has
been the prevailing Dogma.
The Knudson two-hit Dogma is being challenged by a
team lead by Gallie7 in a large international collaborative
study of 1068 cases of unilateral sporadic retinoblastomas
involving five laboratories across five countries (Canada,
Netherlands, Germany, France, and New Zealand). This
group7 identified 29 cases without Rb mutations (2.9%) and
27 of those have elevated MYCN copy numbers (16 cases
with very high copy numbers (28–121)). MYCN is a member
of the MYC family of transcription factors. Amplification of
MYCN (MYCNA) is most notably associated with neuroblas-
toma, where it is associated with how aggressive the disease
is and resistance to therapy.
These 27 cases labeled MYCN RB were characterized by
distinctive histological features. These features include,
undifferentiated cells with large nucleoli and indications of
necrosis and apoptosis, they have markers of embryonic
retina (meeting the definition of retinoblastoma as a blast
cell–cell tumor arising from the retina) but they resemble neu-
roblastoma cells and lack the nuclear molding and Flexner
Wintersteiner rosettes seen in classic retinoblastoma. These
tumors were large and aggressive and presented at a very
early age of diagnosis (median age at diagnosis for MYCN
RB was 4.5 months).
The very early presentation of MYCN RB, the absence of
RB1 mutations, a functional RB1 protein and high MYCN
amplification in a genome with a fairly stable copy number
suggest that these tumors arise by somatic MYCN oncogene
amplification in a retinal progenitor cell. The method by
which MYCN amplification is initiated and whether MYCN
amplification alone is sufficient to initiate retinoblastoma,
has not been elucidated. In retinal cells, the MYCN protein
can support cell division without activation of the E2F familyProduction and hosting by Elsevier
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134 Editorialof transcription factors. Presumably, unregulated MYCN
expression associated with high-level gene amplification in
MYCN RB tumors promotes cell division by indirect inactiva-
tion of the RB1 protein.
Hence, there is now a new hypothesis of ‘one-hit’ with
amplification of the MYCN oncogene as being sufficient to
cause retinoblastoma. Therefore the condition is no more
likely to repeat in siblings or cause another cancer in the pa-
tients than in the general population. Classic RB, in contrast,
often causes other cancers later in life such as Osteosarcoma.
Therefore the diagnosis of MYCN RB can save patients from
invasive follow-up which includes several examinations under
anesthesia. It will also affect the clinical management in cases
of MYCN RB since as this study suggests, the disease is par-
ticularly aggressive and since the other eye will not become
involved, attempt to salvage the eye on the assumption of
heritable disease in young children and could incur high
treatment morbidity and failure to cure these aggressive
oncogene-driven MYCN RB. Therefore, enucleation or surgi-
cal removal of the MYCN-RB tumors would be the correct
therapeutic course. However, the question remains whether
this type of MYCN RB would benefit from an anti-MYCN
treatment? This is yet another challenge for the future.
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